ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
February 15 2024 - 11:26AM
Business Wire
Access here the full press release
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, today acknowledges that
the Phase 3 AEGIS-II study evaluating the efficacy and safety of
CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to
placebo in reducing the risk of major adverse cardiovascular events
(MACE) in patients following an acute myocardial infarction (AMI),
did not meet its primary efficacy endpoint of MACE reduction at 90
days.
About CER-001 CER-001 is a novel engineered recombinant
human apoA-I that was designed to mimic the structural and
functional biological properties of natural, nascent HDL, also
known as pre-β HDL, and has been shown to perform all steps of the
Reverse Lipid Transport pathway (RLT), the only natural pathway
responsible for lipid elimination.
Administered CER-001 particles increase transient apoA-I and the
number of HDL particles and promote the elimination of trapped
cholesterol and lipids in tissues in the absence of LCAT enzyme for
example, but also the elimination of bacterial lipid endotoxin
(LPS) in the case of sepsis. HDL particles are then recognized by
the liver, leading to the elimination of these transported lipids
via a process called Reverse Lipid Transport (RLT).
About ABIONYX Pharma ABIONYX Pharma is a next-generation
biotech company focused on developing innovative medicines in
diseases where there is no effective or existing treatment, even
the rarest ones. The company expedites the development of novel
therapeutics through an extensive expertise in lipid science and a
differentiated apoA-I -based technology platform. ABIONYX Pharma is
committed to radically improving treatment outcomes in sepsis and
critical care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215490264/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From May 2024 to Jun 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Jun 2023 to Jun 2024